Cargando…

Drug repurposing in COVID-19: A review with past, present and future

The coronavirus SARS-CoV-2 which causes the COVID-19 disease is a global public health emergency. Coronavirus are single-stranded positive-sense RNA viruses and their genome size is approximately 30 kb, which encodes some important structural proteins. The interaction between viral Spike protein and...

Descripción completa

Detalles Bibliográficos
Autores principales: Srivastava, Kamna, Singh, Mohan Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387125/
https://www.ncbi.nlm.nih.gov/pubmed/34462734
http://dx.doi.org/10.1016/j.metop.2021.100121
_version_ 1783742391604215808
author Srivastava, Kamna
Singh, Mohan Kumar
author_facet Srivastava, Kamna
Singh, Mohan Kumar
author_sort Srivastava, Kamna
collection PubMed
description The coronavirus SARS-CoV-2 which causes the COVID-19 disease is a global public health emergency. Coronavirus are single-stranded positive-sense RNA viruses and their genome size is approximately 30 kb, which encodes some important structural proteins. The interaction between viral Spike protein and ACE2 on the host cell surface is of significant interest since it initiates the infection process. This review will focus on the effectiveness of reuse of currently used drugs against COVID-19, including clinical trials, molecular docking, and computational modelling approach. METHODS: A systematic search in Pubmed, MEDLINE, EMBASE was conducted from from January 2020 to July 2021. Applying computational, clinical and experimental approaches, numerous drugs such as remdesivir, favipiravir, ribavirin, lopinavir, ritonavir, tocilizumab have been repurposed and have shown promising protection against SARS-CoV2 both in vitro and in clinical conditions. Although there is only one repurposed drug approved by the U.S. Food and Drug Administration (FDA) to treat coronavirus disease 2019 (COVID-19), i.e, Remdesivir. However, the FDA withdrew the authorization of the drugs Hydroxychloroquine and chloroquine,that are not effective for COVID-19 and can also cause serious heart problems. Molecular coupling would be the ideal technique to identify such therapeutic agents against COVID19.
format Online
Article
Text
id pubmed-8387125
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83871252021-08-26 Drug repurposing in COVID-19: A review with past, present and future Srivastava, Kamna Singh, Mohan Kumar Metabol Open COVID-19 in Metabolism The coronavirus SARS-CoV-2 which causes the COVID-19 disease is a global public health emergency. Coronavirus are single-stranded positive-sense RNA viruses and their genome size is approximately 30 kb, which encodes some important structural proteins. The interaction between viral Spike protein and ACE2 on the host cell surface is of significant interest since it initiates the infection process. This review will focus on the effectiveness of reuse of currently used drugs against COVID-19, including clinical trials, molecular docking, and computational modelling approach. METHODS: A systematic search in Pubmed, MEDLINE, EMBASE was conducted from from January 2020 to July 2021. Applying computational, clinical and experimental approaches, numerous drugs such as remdesivir, favipiravir, ribavirin, lopinavir, ritonavir, tocilizumab have been repurposed and have shown promising protection against SARS-CoV2 both in vitro and in clinical conditions. Although there is only one repurposed drug approved by the U.S. Food and Drug Administration (FDA) to treat coronavirus disease 2019 (COVID-19), i.e, Remdesivir. However, the FDA withdrew the authorization of the drugs Hydroxychloroquine and chloroquine,that are not effective for COVID-19 and can also cause serious heart problems. Molecular coupling would be the ideal technique to identify such therapeutic agents against COVID19. Elsevier 2021-08-26 /pmc/articles/PMC8387125/ /pubmed/34462734 http://dx.doi.org/10.1016/j.metop.2021.100121 Text en © 2021 Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle COVID-19 in Metabolism
Srivastava, Kamna
Singh, Mohan Kumar
Drug repurposing in COVID-19: A review with past, present and future
title Drug repurposing in COVID-19: A review with past, present and future
title_full Drug repurposing in COVID-19: A review with past, present and future
title_fullStr Drug repurposing in COVID-19: A review with past, present and future
title_full_unstemmed Drug repurposing in COVID-19: A review with past, present and future
title_short Drug repurposing in COVID-19: A review with past, present and future
title_sort drug repurposing in covid-19: a review with past, present and future
topic COVID-19 in Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387125/
https://www.ncbi.nlm.nih.gov/pubmed/34462734
http://dx.doi.org/10.1016/j.metop.2021.100121
work_keys_str_mv AT srivastavakamna drugrepurposingincovid19areviewwithpastpresentandfuture
AT singhmohankumar drugrepurposingincovid19areviewwithpastpresentandfuture